SEC Form 10-Q filed by Genelux Corporation
$GNLX
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/29/2024 | $8.00 | Buy | Guggenheim |
| 8/28/2024 | $10.00 | Buy | ROTH MKM |
| 11/27/2023 | $35.00 | Buy | H.C. Wainwright |
| 9/12/2023 | $40.00 | Buy | Maxim Group |
| 2/15/2023 | $10.00 | Speculative Buy | The Benchmark Company |
Guggenheim initiated coverage of Genelux with a rating of Buy and set a new price target of $8.00
ROTH MKM initiated coverage of Genelux with a rating of Buy and set a new price target of $10.00
H.C. Wainwright initiated coverage of Genelux with a rating of Buy and set a new price target of $35.00